BOSTON--(BUSINESS WIRE)--Today Obagi Medical Products, Inc. (Nasdaq:OMPI), the leader in topical aesthetic and therapeutic skin health systems, announced the results of a meta-analysis of 23 randomized controlled clinical trials (RCTs) that compared the company’s patented solubilized 5 percent BPO (sBPO) against existing 5 percent BPO, 1-1.2 percent clindamycin (CL) and combination BPO/CL products in reducing acne lesions. The announcement was made at the American Academy of Dermatology’s (AAD) Summer Academy Meeting in Boston, Mass. The data from the meta-analysis, using data adjusted for each study’s size, shows that this new 5 percent sBPO has an equal to superior lesion reduction profile when compared to the leading prescription BPO, combination BPO/CL and topical CL products.
